Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct gene-editing experiments. The device, CRISPR-GPT, is an artificial intelligence lab ...

CRISPR Therapeutics’ stock is surging as in-vivo therapies show promise. Learn about CRSP stock's risks, long-term upside, ...

A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...

In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...

In early October 2025, Intellia Therapeutics presented new clinical results at the European Society of Gene & Cell Therapy Congress, highlighting long-term safety and efficacy data for its ...

Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile--The AATD ...

MIT scientists have found a way to make gene editing far safer and more accurate — a breakthrough that could reshape how we ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the ...